Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022633 · ClinicalTrials.gov registry record · Phase 2
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT00022633 is a Phase 2 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 65 participants.
The verdict
NCT00022633, a Phase 2 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and paclitaxel in treating patients who have advanced or recurrent cancer of the urinary tract.
Interventions
- DRUG paclitaxel
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2001-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022633
The ClinicalTrials.gov registry entry for NCT00022633 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT00022633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00022633 about?
NCT00022633 is a clinical study titled "S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and paclitaxel in treating patients who have advan...
What is the current status of trial NCT00022633?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2001-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00022633?
The interventions under investigation include: paclitaxel (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00022633?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.